SUTENT for Malignant urinary tract neoplasm: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 9 adverse event reports in the FDA FAERS database where SUTENT was used for Malignant urinary tract neoplasm.
Most Reported Side Effects for SUTENT
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Disease progression | 226 | 18.9% | 84 | 30 |
| Death | 225 | 18.8% | 225 | 37 |
| Diarrhoea | 164 | 13.7% | 23 | 40 |
| Fatigue | 140 | 11.7% | 12 | 23 |
| Nausea | 119 | 9.9% | 19 | 36 |
| Decreased appetite | 78 | 6.5% | 15 | 25 |
| Vomiting | 73 | 6.1% | 20 | 30 |
| Asthenia | 67 | 5.6% | 13 | 27 |
| Oral pain | 66 | 5.5% | 10 | 10 |
| Dysgeusia | 63 | 5.3% | 6 | 9 |
| Hypertension | 59 | 4.9% | 6 | 20 |
| Stomatitis | 58 | 4.8% | 8 | 12 |
| Pain in extremity | 53 | 4.4% | 9 | 9 |
| Renal cell carcinoma | 53 | 4.4% | 28 | 8 |
| Weight decreased | 51 | 4.3% | 3 | 12 |
Other Indications for SUTENT
Renal cancer (272)
Renal cell carcinoma (247)
Metastatic renal cell carcinoma (157)
Gastrointestinal stromal tumour (83)
Neoplasm malignant (52)
Renal cancer metastatic (45)
Pancreatic neuroendocrine tumour (19)
Pancreatic carcinoma (12)
Clear cell renal cell carcinoma (10)
Thyroid cancer (8)
Other Drugs Used for Malignant urinary tract neoplasm
BEVACIZUMAB (156)
PAZOPANIB (97)
ERLOTINIB (75)
ATEZOLIZUMAB (73)
CABOZANTINIB S-MALATE (31)
SUNITINIB MALATE (28)
AXITINIB (23)
EVEROLIMUS (13)
PEMBROLIZUMAB (11)
CAPECITABINE (8)